



# Impact of Chalcone in Biofilm Formation of Clinical and Environmental Antibiotic Resistant *Pseudomonas aeruginosa* Isolated in Kut City

Mustafa A. khadhem<sup>1</sup>, Wasan A. Gharbi<sup>2</sup>

<sup>1</sup>Ministry of Health, Medical technician at Wasit Health Department

<sup>2</sup>Institute of Genetic Engineering and Biotechnology for Post Graduate Studies, University of Baghdad

Received: 1/6/2022 Accepted: 31/10/2022 Published: December 20, 2022

**Abstract:** Objectives: *Pseudomonas aeruginosa* continues to be the most common pathogen in the nosocomial settings. This organism shows the high level of resistance against various groups of antibiotics. Therefore, this study was conducted to find out the antimicrobial resistance effects of *Pseudomonas aeruginosa* and the role chalcone in the biofilm formation. Materials and Methods: A total isolates of *P. aeruginosa* were collected from burn, wound, sputum and Patient room VITEK-2 System, a standard technique, was used to perform antibiotic susceptibility testing. The broth microdilution method was used to determine the MIC of the chalcone using the 96-well microtiter plate. Results: Cetrimide agar used to isolate and diagnose of *P. aeruginosa*, among 111 (61.78%) clinical isolation and 7 (35%) environmental samples, then full identification of *P. aeruginosa* using the conventional biochemical tests. The antibiotic susceptibility test for thirteen antibiotics was performed by the standard disk diffusion method, and the results showed that 48 isolate of *p. aeruginosa* was multi-drug resistance with (70-100) %, 53 isolates (50-70) %, and 17 isolates with (30-50) % resistance. Ten multi-drug resistant isolates of *P. aeruginosa* were used to examine their ability in biofilm formation Microtiter plate methods. The results showed that all the isolates had strong biofilm production except isolates No. 4, 7, and 9 which was moderate. The broth microdilution method was used to determine the MIC of the chalcone using the 96-well microtiter plate. The result showed that the MIC values of the chalcone compound on all *P. aeruginosa* isolates were 1000 mg/ml except for isolates No.4, 7, and 9 which were 500 mg/ml. Furthermore, chalcone inhibited 100% of the biofilm formation of *P. aeruginosa* isolates in 500 µg/ml, and reduction the biofilm formation in concentration 32.25 µg/ml.

**Keywords:** *Pseudomonas aeruginosa*, Antibiotics resistant, Chalcone.

**Corresponding author:** (Email: mustafamhmd504@gmail.com).

## Introduction

The diverse opportunistic pathogen *Pseudomonas aeruginosa* (*P. aeruginosa*) is thought to be a major factor in an increasing number of different life-threatening infections (1). Multidrug-resistant *P. aeruginosa* strains, in particular, have caused major issues in a number of nations, such as Iraq. Antimicrobial therapy is a difficult challenge due to the rising incidence of

nosocomial infections caused by strains of *P. aeruginosa* that are multidrug-resistant (MDR), extensively drug-resistant (XDR), and pandrug-resistant (PDR) (2). Because of both acquired and intrinsic resistance to various effective groups of antibiotics, *P. aeruginosa* infections are problematic. Limited permeability regarding the outer membrane, the generation of inducible  $\beta$ -lactamase, and the

Multidrug Efflux System are the causes of intrinsic resistance (3). *P. aeruginosa* was the 3rd most frequent cause of nosocomial urinary tract infections (UTIs), the 2nd most frequent cause of nosocomial pneumonia, and the seventh most frequent cause of nosocomial bacteremia (4).

*P. aeruginosa* is one of the virulent agents with a propensity to the diverse opportunistic pathogen *Pseudomonas aeruginosa* (*P. aeruginosa*) is thought to be a major factor in an increasing number of different life-threatening infections (1). Multidrug-resistant *P. aeruginosa* strains, in particular, have caused major issues in a number of nations, such as Iraq. Antimicrobial therapy is a difficult challenge due to the rising incidence of nosocomial infections caused by strains of *P. aeruginosa* that are multidrug-resistant (MDR), extensively drug-resistant (XDR), and pandrug-resistant (PDR) (2). Because of both acquired and intrinsic resistance to various effective groups of antibiotics, *P. aeruginosa* infections are problematic. Limited permeability regarding the outer membrane, the generation of inducible  $\beta$ -lactamase, and the Multidrug Efflux System are the causes of intrinsic resistance (3). They could create pigments like pyocyanine (green blue) and pyoverdine (yellow green) fluorescence and are nonspore-forming (5). Since *P. aeruginosa* is a very common cause of wound and burn infections, it is considered to be one of the curses of burn units (6). *P. aeruginosa* frequently thrives in clinical settings, and there are numerous reports regarding multiple resistant strains of *P. aeruginosa* being discovered from hospital bed rails, basins, floors, and the hands of medical personnel. This poses one of the biggest challenges in treating infections caused by this bacterium. Because of patient-

to-patient transfers, multidrug-resistant clones could persist in hospitals for several years (7). This is one of the primary etiologies behind the high patient morbidity and mortality rates (8). *P. aeruginosa* represents one of the Gram-negative opportunistic pathogens that had demonstrated multi-resistant infections in both the hospital and community environment (9). Nosocomial UTIs, wounds, burns, endocarditis, and otitis externa are all frequently caused by *P. aeruginosa*. These sites are also where *P. aeruginosa* could invade the bloodstream, causing bacteremia, a systemic infection (10, 11).

### Materials and methods

This prospective study was conducted between 17/10/2021 to 5/2/2022.

### VITEK-2 System

The bacteria were put into Mannitol salt agar plates, and they were after that incubated at a temperature of 37 Celsius overnight. Then, a single colony was removed and placed in solution. By using VITEK (Densichek/BioMerieux), the bacterial suspension's turbidity was brought into compliance with the McFarland 0.50 standard in 0.45 % sodium chloride. Bacterial suspension tubes as well as the VITEK 2 ID-Gp (Gram Positive) card were after that manually put into VITEK-2 system. The next software procedures were carried out in accordance with the directions provided by the manufacturer (BioMerieux, France) (12).

### Isolation of bacteria

All the clinical samples were inoculated on MacConkey, ceftrimide and blood agar. The isolates were recognized using the standard

laboratory protocol for the identification of *P. aeruginosa*).

#### **Determination of minimum inhibitory concentration (MIC) of chalcone**

The broth microdilution method was used to determine the (MIC) of the Chalcone using the 96-well microtiter plate. The working solution of the Chalcone was prepared at 2000 µg/ml in broth and serial two-fold dilutions of Chalcone were prepared directly on the plate to make the concentrations 2000-15.62 µg/ml. 100 µl of the prepared chalcone was introduced into the first wells in row A. Rows B-H in columns had 100 µl of the broth alone. Twofold serial dilutions using micropipette were done systematically down the columns (from rows A-H). 100 µl was removed from the starting concentrations in row A and transferred to the next row with the 100µl broth, properly mixed, and the procedure was repeated up to the last row (H) where the last 100µl was discarded. This brings the final volume in all the test wells with the Chalcone to 100 µl except the column which had 200 µl of the broth that served as sterility control. 100µl of the  $1 \times 10^6$  CFU/ ml bacterial inoculum was transferred into all the wells except the negative control.

Microtiter plates were incubated at 37°C for 18-20 hrs. After incubation, 20 µl of resazurin dye was added to all the wells and incubated for 30 minutes to observe any color changes. The Minimum Inhibitory Concentrations were determined visually in broth micro dilutions as the lowest concentrations of the extracts at which no color changed from blue to pink in the resazurin broth assay (13).

#### **Assessment of biofilm formation**

Quantification of biofilm formation by *P. aeruginosa* was assessed as described by Patel *et al.* (14); all isolates were grown over night in Brain Heart Infusion Broth at 37°C. Each isolate was transferred to tryptic soy broth (TSB) containing 1% glucose and mixed well by pipetting. A suspension of the bacterial isolate was adjusted to McFarland No. 0.5 turbidity standard.

A volume (200 µl) of each isolates culture was added, in triplicate, to a sterile 96 wells microtiter plate with a flat bottom. The plate was covered with their lids and incubated under aerobic conditions at 37°C for 24h. After the incubation period, the planktonic cells were rinsed twice with distilled water to remove the unattached bacteria. The adhering bacterial cells in each well were fixed with 200 µl of absolute methanol for 20 min at room temperature. The adhering cells were stained by adding 200 µl of 0.1% crystal violet to each well for 15 min. Once the staining reaction has completed, the excess stain was removed by repeated washing (2-3 washes) with distilled water. The plate was dried by leaving them at room temperature for approximately 30 min to ensure they were completely dry, finally, 33% acetic acid was added to fix the stain.

Optical density (OD) readings were determined using an ELISA auto reader at a wavelength of 630 nm. Average of OD values of sterile medium were calculated and subtracted from all test values. Cut off value (OD<sub>c</sub>) was calculated, which can provide categorization of isolates as biofilm producer or not (15).

**OD<sub>c</sub>:** Average OD of negative control + (3 × standard deviation (SD) of Negative control), **OD isolate:** Average OD of isolate – OD<sub>c</sub>.

By the calculation of cutoff value (ODc), the result of biofilm detected as below:

$OD \leq ODc$  (no biofilm production).

$ODc < OD \leq 2 \times ODc$  (weak biofilm production).

$2 \times ODc < OD \leq 4 \times ODc$  (moderate biofilm production).

$4 \times ODc < OD$  (strong biofilm production).

## Result and discussion

### Antibiotic susceptibility testing

In the present study, the antibiotic susceptibility test of the 118 isolates (111 clinical and 7 environmental) of *P. aeruginosa* was performed on 13 antibiotics represented by Ticarcillin (TIC), Piperacillin (PRL), Imipenem (IMI), Tobramycin (TOB), Piperacillin/Tazobactam (PRZ), Ticarcillin/Clavulanic acid (TIV), Ceftazidime (CAZ), Gentamicin (GN), Cefepime (CFM), Meropenem (MER), Colistin (CO), Amikacin (AK) and Ciprofloxacin (CIP) using the disc diffusion method.

The antibiogram of the studied isolates revealed that 48 isolate of *p. aeruginosa* was multi-drug resistance with (70-100) %, 53 isolates (50-70) %, and 17 isolates with (30-50) % resistance. Furthermore, the isolates were resistance 100% to (TIC and PRL), 95.67, 94.91, 90.67, 80.50 and 74.57% to (IMI, CAZ, TOB, CFM and GN) respectively, followed by 64.40, 55.08 and 47.45% to (TIV, PRZ and MER) respectively, while the resistance were 32.20, 30.50 and 25.42% to (CIP, AK and CO) respectively.

The result showed, the isolates were less resistance to Colistin, and the susceptibility rate was 74.45%. This finding was disagreement with previous studies by Burgh *et al.* (16) in Kurdistan, Iraq; Izadi Pour Jahromi *et al.* (17) in Iran and Hussein *et al.* (18) in

Wasit, Iraq, which the susceptibility rate was (96%), (97.5%), and (98.03%) respectively, while Khudair and Mahmood (19) in Baghdad, Iraq and Najeeb *et al.* (20) in Baquba City, Iraq reported that the Colistin was susceptible to *P. aeruginosa* isolates in (60%) and (65%) respectively.

This ability is either normal or acquired through mutations in their genetic material or through the horizontal transference of genes (21). *P. aeruginosa* is considered a major cause of hospital-acquired infections due to its high antibacterial resistance (22).

Aminoglycosides, such as gentamicin are multifunctional hydrophilic sugars that possess several amino and hydroxyl functionalities that can inhibit prokaryotic protein synthesis in a bacterial cell by binding to 30S subunit of the ribosome, and changing the conformation of the A site to one that resembles the one induced by an interaction between cognate tRNA and mRNA (23). The reason behind the bacterial resistance to these antibiotics is due to the production of  $\beta$ -lactamase enzymes, which acted to destroy the  $\beta$ -lactams ring thereby led to modification of antibiotics structure and spoilage their effects (24).

*P. aeruginosa* resistance to numerous antibiotics, resulting from excessive antibiotic administration, is now leading to the accumulation of antibiotic resistance and cross-resistance between antibiotics and the appearance of multi-drug resistant MDR forms of *P. aeruginosa* (25). In the present study, out of the total *P. aeruginosa* isolates, ten isolates (8 clinical and 2 environmental) with multi-drug resistance are selected for further experiments, as shown in Table (1).

Table (1): Antibiotic susceptibility test of ten *P. aeruginosa*

Antibiotic Isolate		TIC	PRL	IMI	TOB	PRZ	TIV	CAZ	GN	CFM	MER	CO	AK	CIP	Percentage of Resistance
<b>Clinical isolates</b>															
P <sub>1</sub>	P <sub>4</sub>	R	R	R	R	R	R	R	R	R	R	S	R	R	92.30%
P <sub>2</sub>	P <sub>8</sub>	R	R	R	R	R	R	R	R	R	R	S	R	R	92.30%
P <sub>3</sub>	P <sub>11</sub>	R	R	R	R	R	R	R	R	R	R	S	R	R	92.30%
P <sub>4</sub>	P <sub>24</sub>	R	R	R	R	R	R	R	R	R	R	S	R	R	92.30%
P <sub>5</sub>	P <sub>27</sub>	R	R	R	R	R	R	R	R	R	R	S	R	R	92.30%
P <sub>6</sub>	P <sub>50</sub>	R	R	R	R	R	R	R	R	R	R	R	R	R	100%
P <sub>7</sub>	P <sub>60</sub>	R	R	R	R	R	R	R	R	R	R	S	R	R	92.30%
P <sub>8</sub>	P <sub>95</sub>	R	R	R	R	R	R	R	R	R	R	R	R	S	92.30%
<b>Environmental isolates</b>															
P <sub>9</sub>	P <sub>117</sub>	R	R	R	R	R	R	R	R	R	R	S	S	S	76.92%
P <sub>10</sub>	P <sub>119</sub>	R	R	R	R	R	R	R	R	R	S	S	S	R	76.92%
<b>Percentage of Resistance</b>		<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>90%</b>	<b>20%</b>	<b>80%</b>	<b>80%</b>	

(P): *Pseudomonas aeruginosa*, (TIC): Ticarcillin, (PRL): Piperacillin, (IMI): Imipenem, (TOB): Tobramycin, (PRZ): Piperacillin/Tazobactam, (TIV): Ticarcillin/Clavulanic acid, (CAZ): Ceftazidime, (GN): Gentamicin, (CFM): Cefepime, (MER): Meropenem, (CO): Colistin, (AK): Amikacin, (CIP): Ciprofloxacin

### Determination the (MIC) of the chalcone on *P. aeruginosa* isolates


The broth microdilution method was used to determine the MIC of the chalcones using the 96-well microtiter plate. A method using the oxidation-reduction colorimetric indicator resazurin has determined the MIC of the antimicrobial agents against *P. aeruginosa*. Resazurin, which is blue in its oxidized state, turns pink when reduced by viable cells and can easily be detected with the naked eyes, and the MIC is determined even without the aid of a spectrophotometer (26).

The result showed that the MIC values of the chalcone compound on all *P. aeruginosa* isolates were 1000 mg/ml except for isolates No.4, 7, and 9 which were 500 mg/ml, as shown in (Table 2) and (Figure 1).

Chalcone is an antibacterial agent with moderate to high activity due to the presence of the reactive  $\alpha$ B-unsaturated system. Their flexibility to

change their structure by incorporating different types of substituent groups into the aromatic ring can potentially achieve a higher potency, lower toxicity, and a wider spectrum of antibacterial activity (27).

Another study tested chalcones for their antibacterial activity against Gram-positive strains *Bacillus subtilis* and *Staphylococcus aureus* and Gram-negative strains *P. aeruginosa* and *Salmonella typhimurium* (28). Chalcone exhibited antibacterial actions via various targets, which mainly include efflux pump inhibitory, interfering DNA replication, and filamentous temperature-sensitive mutant Z. (29). Dhaliwal *et al.* (30) found that chalcone compounds can inhibit diverse targets of antibiotic-resistance development pathways; therefore, they overcome resistance, and bacteria become susceptible to antibacterial compounds.



(p): *P. aeruginosa* isolates, (G<sup>+</sup>): Control positive (Bacteria + Media), (G<sup>-</sup>): Control negative (Media only).

Figure (1): MIC of chalcone on *P. aeruginosa* isolates.

Table (2): MIC of chalcone on *P. aeruginosa*

Isolate	Chalcone (µg/ml)	
	MIC	
P <sub>1</sub>	1000	
P <sub>2</sub>	1000	
P <sub>3</sub>	1000	
P <sub>4</sub>	500	
P <sub>5</sub>	1000	
P <sub>6</sub>	1000	
P <sub>7</sub>	500	
P <sub>8</sub>	1000	
P <sub>9</sub>	500	
P <sub>10</sub>	1000	

(P): *P. aeruginosa* isolate.

### Biofilm of *Pseudomonas aeruginosa*

The microtiter plate method was used to determine the biofilm formation of multi-drug resistant isolates. The results showed that all the isolates had strong biofilm production except isolates No. 4, 7, and 9 which was moderate as shown in Table (3). Biofilms are of utmost medical relevance with biofilms being abundantly present in sputum samples of individuals with cystic fibrosis, pacemakers, diabetic wounds, and in many other infections. However, most

of the early conventional medical microbiological work has been based on planktonic bacteria. The last two decades clearly suggest that nearly 80% of disease progression is caused by biofilms (31). *P. aeruginosa* pathogen is known to form successful biofilms and these biofilms are often the root of serious medical complications (32). Al-Saray(33) reported that 95.56% of *P. aeruginosa* isolates have the ability to form biofilm.

Table (3): Biofilm formation of *P. aeruginosa* using the microtiter plate method

Clinical isolate	Source of Isolate	Biofilm Production
P <sub>1</sub>	Burn	Strong
P <sub>2</sub>	Burn	Strong
P <sub>3</sub>	Wound	Strong
P <sub>4</sub>	Wound	Moderate
P <sub>5</sub>	Wound	Strong
P <sub>6</sub>	Wound	Strong
P <sub>7</sub>	Wound	Moderate
P <sub>8</sub>	Wound	Strong
P <sub>9</sub>	Wound	Moderate
P <sub>10</sub>	Wound	Strong

(P): *P. aeruginosa* isolate.

### Antibiofilm activity of chalcone in *P. aeruginosa* isolates

Biofilm is a densely packed community of microbial cells that attach and grow on living or nonliving surfaces and surround themselves with secreted polymers. Biofilm associated infections are often difficult to treat because of multi drug resistance, so it is important to identify new and effective molecules against bacterial biofilm formation (34).

In this study, chalcone inhibited 100% of the biofilm formation of *P. aeruginosa* isolates in 500 µg/ml, and reduction the biofilm formation in concentration 32.25 µg/ml, as shown in Table (4). ESKAPE pathogens, includes *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa* and *Enterobacter* spp., have received wide attention due to their immense clinical importance. Several studies indicate that the biofilm mediated infections associated with these bacteria serve to increase their resistance towards antibiotics, necessitating the urgent need to develop more efficacious and safer drugs. Naturally occurring chalcones, which are precursors of flavonoids, have received wider attention for their potent antibacterial and antibiofilm activity(35). Dusan *et al.* (36) demonstrated the antibacterial activity of chalcone

molecules and proved their ability to act inhibitory or bactericidal on some multi-resistant clinical isolates of *A. baumannii* and *P. aeruginosa*, in a dose-dependent manner. Besides, these compounds were able to significantly inhibit some of the important virulence factors when applied at sub-inhibitory concentrations, such as biofilm production and motility of *A. baumannii* and *P. aeruginosa*. Pereira *et al.* (2022) (37) showed the potential of chalcone compounds regarding the reversion of bacterial resistance and showed a higher ability than reserpine to inhibit biofilm formation of resistant *P. aeruginosa*. Recently, as a result of the search for new antimicrobial adjuvants, some chalcones have demonstrated the ability to potentiate the antimicrobial effect, as well as on biofilm inhibition (38,39). Flavonoids cause bacterial aggregation by their partial lysis, which leads to membrane fusion, and consequently reduces the active nutrient uptake via a smaller membrane area, the anti biofilm activity of chalcone attributed to the forming a cage-like structure around the cell wall to allow the entry of the active moiety of the drug into the cell (40). On the other hand, Lima *et al.* (41) showed comparatively better antibiofilm activity against *P. aeruginosa* with MIC 256 µg/ml.

**Table (4): Biofilm formation of *Pseudomonas aeruginosa* isolates before and after treatment with chalcone.**

Clinical isolatee	Source of isolate	Before treatment	After Treatment Concentration ( $\mu\text{g/ml}$ )						
			32.25	64.5	125	250	500	1000	2000
P1	Burn	Strong	Moderate	Moderate	Week	Week	No Biofilm	No Biofilm	No Biofilm
P2	Burn	Strong	Moderate	Moderate	Week	Week	No Biofilm	No Biofilm	No Biofilm
P3	Wound	Strong	Moderate	Moderate	Week	Week	No Biofilm	No Biofilm	No Biofilm
P4	Wound	Moderate	Week	Week	No Biofilm	No Biofilm	No Biofilm	No Biofilm	No Biofilm
P5	Wound	Strong	Moderate	Moderate	Week	No Biofilm	No Biofilm	No Biofilm	No Biofilm
P6	Wound	Strong	Moderate	Moderate	Week	Moderate	No Biofilm	No Biofilm	No Biofilm
P7	Wound	Moderate	Week	Week	No Biofilm	No Biofilm	No Biofilm	No Biofilm	No Biofilm
P8	Wound	Strong	Moderate	Moderate	Week	No Biofilm	No Biofilm	No Biofilm	No Biofilm
P9	Wound	Moderate	Week	Week	No Biofilm	No Biofilm	No Biofilm	No Biofilm	No Biofilm
P10	Wound	Strong	Moderate	Moderate	Week	Week	No Biofilm	No Biofilm	No Biofilm

## Conclusion

The isolates were resistance 100% to (TIC and PRL), 95.67, 94.91, 90.67, 80.50 and 74.57% to (IMI, CAZ, TOB, CFM and GN) respectively, followed by 64.40, 55.08 and 47.45% to (TIV, PRZ and MER) respectively, while the resistance was 32.20, 30.50 and 25.42% to (CIP, AK and CO) respectively. Chalcone display a high antibacterial agent on *P. aeruginosa* despite the fact that bacterial isolates were resistant to commonly used antibiotics. Furthermore, chalcone had an excellent reduction of biofilm formation in *P. aeruginosa*.

## Acknowledgment

The authors would like to thank The Al- Karama Teaching Hospital, Al-Kut Hospital for Women and Children, Al-Zahra Teaching Hospital and MSC Ali muwafak, PH Hayder Mahdi and Murtada F. Musa for their support in completing this study.

## References

- Rashid, A.; Akram, M.; Kayode, O.T. and Kayode, A.A. (2020). Clinical features and epidemiological patterns of infections by

multidrug resistance *Staphylococcus aureus* and *Pseudomonas aeruginosa* in Patients with Burns. biomedical journals Science Technology Research., 25 (4): 19272-19278.

- El Zowalaty, M. E.; Al Thani, A. A.; Webster, T. J.; El Zowalaty, A. E.; Schweizer, H. P. and Nasrallah, G. K. (2015). *Pseudomonas* Immunocompromised Patients: Relation to Initial Antibiotic Therapy and Survival Jpn. Journal of Infectious Diseases, 69: 91–96.
- Mohamad, S.M.; Rostami, S.; Zamanzad, B.; Gholipour, A. and Drees, F. (2017). Detection of exotoxins and antimicrobial susceptibility pattern in clinical *Pseudomonas aeruginosa* isolates. Avicenna Journal of Clinical Microbiology and Infection, 4 (4): 1-6.
- AL-Kaisse, A.A. (2013). Molecular detection of OXA-4, OXA-10 and VEB- 1 genes in *Pseudomonas aeruginosa* isolated from burn's wound patients. Genetic Engineering and Biotechnology Institute For Postgraduate Studies University of Baghdad. (M. Sc Thesis.)
- Willcox, M. D. (2007). *Pseudomonas aeruginosa* infection and inflammation during contact lens wear: a review. Optometry and Vision Science: Official Publication of the American Academy of Optometry, 84(4): 273-278.
- Saaq, M.; Ahmed, S. and Zaib, M. (2015). Burn wound infections and antibiotic



- susceptibility patterns at Pakistan institute of medical science. *World Journal Plastic Surgery*, 4(1):9-15.
7. Perez, F.; Hujer, M.; Marshal, M.; Ray, A.; Rather, P. and Suwantarant N. (2014). Extensively drug-resistant *Pseudomonas aeruginosa* isolates containing blaVIM-2 and elements of Salmonella genomic island 2: A new genetic resistance determinant in Northeast Ohio. *Antimicrobial Agents Chemotherapy*, 58(10): 5929-5935.
  8. Pang, Z.; Raudonis, R.; Glick, B. R.; Lin, T. J. and Cheng, Z. (2019). Antibiotic resistance in *Pseudomonas aeruginosa*: mechanisms and alternative therapeutic strategies. *Biotechnology Advances*, 37(1): 177-192.
  9. Tille, P. (2015). *Bailey and Scott's diagnostic microbiology Book*. Elsevier Health Sciences.
  10. Al-ammary, M. J. (2013). Detection of some carbapenem-resistant genes of *Pseudomonas aeruginosa* isolates from Al-Hilla teaching hospital. research College of Science. Babylon. Univ. (M. Sc. Thesis in Microbiology).
  11. Migiyama, Y.; Yanagihara, K.; Kaku, N.; Harada, Y.; Yamada, K. and Nagaoka, K. (2016). *Pseudomonas aeruginosa* Bacteremia among Immunocompetent and Immunocompromised Patients: Relation to Initial Antibiotic Therapy and Survival. *Japanese Journal of Infectious Diseases*, 69(2): 91-96.
  12. Ling, T. K.; Liu, Z. K. and Cheng, A. F. (2003). Evaluation of the VITEK 2 system for rapid direct identification and susceptibility testing of gram-negative bacilli from positive blood cultures. *Journal of Clinical Microbiology*, 41(10): 4705-4707.
  13. Ohikhen, F.U.; Wintola, O.A.E and Afolayan, A.J. (2017). Evaluation of the Antibacterial and Antifungal Properties of *Phragmanthera capitata* (Sprengel) Balle (Loranthaceae), a Mistletoe Growing on Rubber Tree, Using the Dilution Techniques. *The Scientific World Journal*, 2017: 9658598.
  14. Patel, F.M.; Goswami, P.N. and Khara, R. (2016). Detection of Biofilm formation in device associated clinical bacterial isolates in cancer patients. *Sri Lankan Journal of Infectious Diseases*, 6(1): 43-50.
  15. Kirmusaoglu, S. (2019). The Methods for Detection of Biofilm and Screening Antibiofilm Activity of Agents. In *Exopolysaccharides- Methods of Preparation and Application*. In technology Open. DOI: [http:// dx.doi.org / 10.5772 / intechopen.84411](http://dx.doi.org/10.5772/intechopen.84411).
  16. Burgh, S.; Maghdid, D. M.; Ganjo, A. R.; Mansoor, I. Y.; Kok, D. J.; Fatah, M. H. *et al.* (2019). PME and other ESBL- positive multiresistant *Pseudomonas aeruginosa* isolated from hospitalized patients in the region of Kurdistan, Iraq. *Microbial Drug Resistance*, 25(1): 32-38.
  17. Jahromi, S.; Mardaneh, J.; Sharifi, A.; Pezeshkpour, V.; Behzad-Behbahani, A.; Seyyedi, N. *et al.* (2018). Occurrence of a multidrug resistant *Pseudomonas aeruginosa* strains in hospitalized patients in southwest of Iran: Characterization of resistance trends and virulence determinants. *Jundishapur Journal of Microbiology*, 11(4): 1-11.
  18. Hussein, Z. K.; Kadhim, H. S. and Hassan, J. S. (2018). Detection of New Delhi metallo-beta-lactamase-1 (blaNDM-1) in carbapenem-resistant *Pseudomonas aeruginosa* isolated from clinical samples in Wasit hospitals. *Iraqi JMS*, 16(3): 239-246.
  19. Khudair, A. N. A. and Mahmood, S. S. (2021). Detection of the Antiseptic Resistance Gene among *Pseudomonas aeruginosa* Isolates. *Iraqi Journal of Science*, 62(1): 75-82.
  20. Najeeb, A. S. and Al-Taai, H. R. R. (2020). Genotyping Diversity of *Pseudomonas aeruginosa* Isolates, Isolated from Baquba City. *Medico Legal Update*, 20(4): 1816-1821.
  21. Sadari, H. and Owlia, P. (2015). Microscopic Study of the effects of subinhibitory concentrations of gentamicin on capsule production of *P. aeruginosa*. *Archives of Iranian Medicine journal*. 4 :18-20.
  22. Emami, S.; Nikokar, I.; Ghasemi, Y.; Ebrahimpour, M.; Araghian, A. and Rajabi, A. *et al.* (2015). Antibiotic resistance pattern and distribution of pslA gene among biofilm producing *Pseudomonas aeruginosa* isolated from waste water of a burn center. *Jundishapur Journal of Microbiology*, 8: 1-5.
  23. Juayang, A. C.; Lim, J. T. and Gallega, C. T. (2017). Five-year antimicrobial susceptibility of *Pseudomonas aeruginosa* from a local tertiary hospital in Bacolod City, Philippines. *Tropical Medicine and Infectious Disease*, 2(3): 28.
  24. Al-Salamy, A. k. and Ali Al-Hilli, E. S. (2012). Antibiotics Susceptibility pattern of *Pseudomonas aeruginosa* that isolated from

- ear, wound and urine samples. Journal of the College of basic Education, 76: 101-110.
25. Yayan, J.; Ghebremedicalhin, B. and Rasche, K. (2015). Antibiotic resistance of *Pseudomonas aeruginosa* in pneumonia at a single university hospital center in Germany over a 10-year period. Plos one, 10: 1-20.
26. Ncube, N. S.; Afolayan, A. J. and Okoh, A. I. (2008). Assessment techniques of antimicrobial properties of natural compounds of plant origin: current methods and future trends. African Journal of Biotechnology, 12(7): 1797-1806.
27. Shaik, A.; Bhandare, R.R.; Palleapati, K.; Nissankararao, S.; Kancharlapalli, V. and Shaik, S. (2020). Antimicrobial, Antioxidant, and Anticancer Activities of Some Novel Isoxazole Ring Containing Chalcone and Dihydropyrazole Derivatives. Molecules, 25: 1047.
28. Konduru, N.K.; Dey, S.; Sajid, M.; Owais, M. and Ahmed, N. (2013). Synthesis and antibacterial and antifungal evaluation of some chalcone based sulfones and bisulfones. European Journal of Medicinal Chemistry, 59: 23–30.
29. Xu, M.; Wu, P.; Shen, F.; Ji, J. and Rakesh, K.P. (2019). Chalcone derivatives and their antibacterial activities: Current development. Bioorganic chemistry, 91: 103133.
30. Dhaliwal, J.S.; Moshawih, S.; Goh, K.W.; Loy, M.J.; Hossain, M.S.; Hermansyah, A. *et al.* (2022). Pharmacotherapeutics Applications and Chemistry of Chalcone Derivatives. Molecules, 27(20): 706.
31. Jamal, M.; Ahmad, W.; Andleeb, S.; Jalil, F.; Imran, M.; Nawaz, T. *et al.* (2018). Bacterial biofilm and associated infections. Journal of the Chinese Medical Association: JCMA, 81(1): 7–11.
32. Patil, A.; Banerji, R.; Kanojiya, P. and Saroj, S. D. (2021). Foodborne ESKAPE biofilms and antimicrobial resistance: lessons learned from clinical isolates. Pathog. Glob. Health, 115(6): 339–356.
33. Al-Saray, Z. A. K. (2016). Effect of gamma rays on some virulence factors from burn and wound isolated bacteria. M.Sc. Thesis. College of Science. Al-Mustansiriya University.
34. Kumar, L.; Chhibber, S. and Harjai, K. (2013). Zinger, one inhibits biofilm formation and improve Antibiofilm efficacy of ciprofloxacin against *Pseudomonas aeruginosa* PAO1. Fitoterapia, 90: 73–78.
35. Ashwini U.; Thokur S. M. and Roopa N. (2021). Escaping ESKAPE: A chalcone perspective. Results in Chemistry, 3: 100229.
36. Dusan U.; Branka I.; Dragana D. B.; Lidija B. and Marina M. (2019). Antimicrobial activity of novel chalcones and modulation of virulence factors in hospital strains of *Acinetobacter baumannii* and *Pseudomonas aeruginosa*, Microbial Pathogenesis, 131: 186-196.
37. Pereira, D.; Duraes, F.; Szemerédi, N.; Freitas-da-Silva, J.; Pinto, E.; Martins-da-Costa, P. *et al.* (2022). New Chalcone-Triazole Hybrids with Promising Antimicrobial Activity in Multidrug Resistance Strains. International Journal of Molecular Sciences, 23(22): 14291.
38. Jesus, A.; Duraes, F.; Szemerédi, N.; Freitas-Silva, J.; da Costa, P.M.; Pinto, E. *et al.* (2022). BDDE-Inspired Chalcone Derivatives to Fight Bacterial and Fungal Infections. Marine drugs, 20(5), 315.
39. Moreira, J.; Durães, F.; Freitas-Silva, J.; Szemerédi, N.; Resende, D.I.S.P.; Pinto, E. *et al.* (2022). New diarylpentanoids and chalcones as potential antimicrobial adjuvants. Bioorganic and Medicinal Chemistry Letters, 67: 128743.
40. Uma, P.; Suresh, J.; Selvaraj, R.; Karthik, S. and Arun, A. (2015). Quinoline based polymeric drug for biological applications: synthesis, characterization, antimicrobial, and drug releasing studies. Journal of biomaterials science. Polymer edition, 26 (2): 128-142.
41. Lima, E.M.; Fernando, L. M.; Felix, L. P.; de Oliveira, Filho, A. A.; Carneiro Neto, A. N.; Moura, R. T. *et al.* (2020). First complete NMR data and theoretical study of an antimicrobial formylated dihydrochalcone from *Psidium guineense* Sw. Natural Product Research, 36(1): 419–423.

42. AL-Fridawy, R. A. K., Al-Daraghi, W. A. H., & Alkhafaji, M. H. (2020). Isolation and Identification of Multidrug Resistance Among Clinical and Environmental *Pseudomonas aeruginosa* Isolates. *Iraqi Journal of Biotechnology*, 19(2).